Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | CDC7 | O00311 | 1/20 | 0.32 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | ERN1 | O75460 | 1/20 | 0.32 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4200301 | 0.85 | IGF1R (0.58) | IGF1RKMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL4206559 | 0.84 | IGF1R (0.60) | IGF1RKMT2AALDH1A1RAB9APOLB | |
| SCHEMBL4201253 | 0.83 | IGF1R (0.56) | IGF1RKMT2AMEN1MAPTALOX15 | |
| SCHEMBL4203371 | 0.83 | IGF1R (0.56) | IGF1RKMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL4198126 | 0.82 | IGF1R (0.55) | IGF1RKMT2AALDH1A1RAB9APOLB | |
| SCHEMBL4195862 | 0.82 | IGF1R (0.55) | IGF1RKMT2AMEN1MAPTKDM4E | |
| SCHEMBL4216016 | 0.81 | IGF1R (0.54) | IGF1RKMT2AKDM4EALDH1A1RAB9A | |
| SCHEMBL4210363 | 0.81 | IGF1R (0.54) | IGF1RKMT2AMAPTKDM4ECTSK | |
| SCHEMBL4198303 | 0.80 | IGF1R (0.56) | IGF1RKMT2AMEN1ALDH1A1RAB9A | |
| SCHEMBL4196034 | 0.80 | IGF1R (0.53) | IGF1RKMT2ABRD4ALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538231-B2 | Tyrosine kinase inhibitors | MERCK & CO, INC. (US) | 2009-05-26 | — | — | US | claimed |
| EP-1651209-A4 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2009-03-04 | — | — | EP | claimed |
| JP-2006528631-A | — | — | 2006-12-21 | — | — | JP | claimed |
| US-20060276514-A1 | Tyrosine kinase inhibitors | MERCK & CO., INC. | 2006-12-07 | — | — | US | claimed |
| EP-1651209-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2006-05-03 | — | — | EP | claimed |
| WO-2005009373-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2005-02-03 | — | — | WO | claimed |
| US-7538231-B2 | Tyrosine kinase inhibitors | MERCK & CO, INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-7538231-B2 | Tyrosine kinase inhibitors | MERCK & CO, INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-7538231-B2 | Tyrosine kinase inhibitors | MERCK & CO, INC. (US) | 2009-05-26 | — | — | US | disclosed |
| EP-1651209-A4 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2009-03-04 | — | — | EP | disclosed |
| US-20060276514-A1 | Tyrosine kinase inhibitors | MERCK & CO., INC. | 2006-12-07 | — | — | US | disclosed |
| EP-1651209-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005009373-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276514-A1 | Tyrosine kinase inhibitors | ABL1, RET, ERBB2 | IGF1R 102/4885KMT2A 1302/4885MEN1 2744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.